Paclitaxel

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results

Retrieved on: 
Thursday, May 9, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Organic compounds, Chemical compounds, Bristol-Myers Squibb, Taxanes, Benzamides, Benzoates, Paclitaxel, Propionates, Oncolytics Biotech, Amgen

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical and corporate developments.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical and corporate developments.
  • Deciphera completed enrollment of 40 patients in Part 1 of the Phase 1b/2 combination study of rebastinib with paclitaxel.
  • The Company expects to report initial data from Part 1 of this study in the second half of 2019.
  • Deciphera announced the appointment of Steve Hoerter as President & Chief Executive Officer, effective March 18, 2019.

Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Retrieved on: 
Thursday, April 25, 2019
Health, Pharmaceutical, General Health, Cancer treatments, Clinical medicine, Organic compounds, Lung cancer, RTT, Antineoplastic drugs, Breakthrough therapy, Bristol-Myers Squibb, Pembrolizumab, Non-small-cell lung carcinoma, Paclitaxel, Melanoma

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Key Points: 
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
  • When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA should be administered prior to chemotherapy when given on the same day.

Cook Medical Provides Patient-Level Paclitaxel Data From Randomised Control Trial

Retrieved on: 
Thursday, April 18, 2019
Health, Biotechnology, Cardiology, Clinical trials, Hospitals, Medical devices, Other Health, Research, Other Science, Science, Organic compounds, Chemical compounds, Evidence-based practices, Clinical research, Benzamides, Benzoates, Paclitaxel, RTT, Randomized controlled trial, Medicine, PTX

This week, Cook Medical made patient-level data from the Zilver PTX randomised control trial (RCT) available by request on cookmedical.com .

Key Points: 
  • This week, Cook Medical made patient-level data from the Zilver PTX randomised control trial (RCT) available by request on cookmedical.com .
  • Cook provides thisdata to encourage further collaboration with researchers to benefit patients with peripheral arterial disease.
  • Cook is the first company with paclitaxel devices to make de-identified patient-level data on these devices publicly available.
  • Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery.

Cook Medical Provides Patient-Level Paclitaxel Data From Randomized Control Trial

Retrieved on: 
Thursday, April 18, 2019
Health, Biotechnology, Cardiology, Clinical trials, Hospitals, Medical devices, Other Health, Research, Other Science, Science, Organic compounds, Chemical compounds, Evidence-based practices, Clinical research, Benzamides, Benzoates, Paclitaxel, RTT, Randomized controlled trial, Medicine, PTX

This week, Cook Medical made patient-level data from the Zilver PTX randomized control trial (RCT) available by request on cookmedical.com .

Key Points: 
  • This week, Cook Medical made patient-level data from the Zilver PTX randomized control trial (RCT) available by request on cookmedical.com .
  • Cook provides thisdata to encourage further collaboration with researchers to benefit patients with peripheral arterial disease.
  • Cook is the first company with paclitaxel devices to make de-identified patient-level data on these devices publicly available.
  • Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery.

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation

Retrieved on: 
Thursday, April 18, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Organic compounds, Chemical compounds, Bristol-Myers Squibb, Benzoates, RTT, Taxanes, Benzamides, Paclitaxel, European Directorate for the Quality of Medicines

Phyton Biotech, a German/North American Plant Cell Fermentation (PCF) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVidas paclitaxel injectable FDF.

Key Points: 
  • Phyton Biotech, a German/North American Plant Cell Fermentation (PCF) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVidas paclitaxel injectable FDF.
  • Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVidas Taxol generic formulation, which is produced in AqVidas new state-of-the-art injectable manufacturing facility located in Dassow, Germany.
  • AqVidas ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to produce AqVidas generic oncology medicines to treat common types of cancer.
  • Approval of ourpaclitaxel injectable FDFby theEuropean Directorate of Quality Medicinesis a major milestone for our company.

Global Drug Eluting Stents Markets, 2024

Retrieved on: 
Monday, April 8, 2019
Organic compounds, Medicine, Interventional cardiology, Medical specialties, Drug-eluting stent, Stent, Everolimus, Paclitaxel, Percutaneous coronary intervention, Steroid eluting sinus stent

DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Drug Eluting Stents Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 8, 2019 /PRNewswire/ -- The "Global Drug Eluting Stents Market 2018-2024" report has been added to ResearchAndMarkets.com's offering.
  • The Global Drug-Eluting Stents Market is Expected to Witness a CAGR of 5.4% During the Forecast Period to Reach Revenue of $5,614.6 Million by 2024.
  • Drug-eluting stents refer to the metal stents that have a coating of drugs such as paclitaxel, everolimus, and also antiproliferative drugs to widen the narrowed blood vessel.
  • The major end-users in the drug eluting stents market are cardiology centers, ambulatory surgery centers (ASCs), and hospitals.

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

Retrieved on: 
Friday, March 22, 2019
Women, Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Radiology, Research, Consumer, Science, Managed care, RTT, Cancer, Organic compounds, Medicine, Oncology, Gynaecological cancer, Gynaecology, Ovarian cancer, Paclitaxel, Pancreatic cancer, Metástasis, Sorafenib

Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
  • We are pleased to begin this trial that has the potential to improve survival in recurrent ovarian cancer.
  • Novocure developed the trial design for INNOVATE-3 after learning the results of its phase 2 pilot trial of Tumor Treating Fields in combination with weekly paclitaxel, the INNOVATE trial.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, March 14, 2019
Health, Biotechnology, Cardiology, Oncology, Pharmaceutical, Cancer, Clinical medicine, Antineoplastic drugs, Lung cancer, Carcinoma, RTT, Breakthrough therapy, Pembrolizumab, Small-cell carcinoma, Non-small-cell lung carcinoma, Paclitaxel, Protein-bound paclitaxel

With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit from combination therapy with KEYTRUDA.

Key Points: 
  • With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit from combination therapy with KEYTRUDA.
  • KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
  • When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA should be administered prior to chemotherapy when given on the same day.
  • KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer

Retrieved on: 
Tuesday, March 12, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, FDA, Clinical medicine, Cancer, Organic compounds, Breast cancer, RTT, Bristol-Myers Squibb, Protein-bound paclitaxel, Cancer treatments, Paclitaxel, Adjuvant therapy, Pancreatic cancer, Triple-negative breast cancer

Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.

Key Points: 
  • Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.
  • Currently, there are more than 130 studies evaluating the use of ABRAXANE in patients with pancreatic cancer in combination with more than 50 novel agents.
  • In September 2013, the U.S. Food and Drug Administration (FDA) approved ABRAXANE in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
  • ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1

Retrieved on: 
Monday, March 11, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Medicine, Clinical medicine, RTT, Organic compounds, Genentech, Immunology, Cancer treatments, Biotechnology, Trastuzumab, HER2/neu, Paclitaxel, Metastatic breast cancer

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients.

Key Points: 
  • At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients.
  • For more than 150 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.